कंपनी का अवलोकन
Synergy CHC Corp. operates within the healthcare sector, specifically functioning in the medical distribution industry to supply consumer health care, beauty, and lifestyle products across the United States, Canada, and the United Kingdom. The firm's product portfolio includes brain health nutritional supplements marketed under the FOCUSfactor brand name, alongside various wellness accessories such as tea, shakes, and lollipops. As of the latest available data, the company holds a market capitalization of $7.25M and reported total revenue of $30.38M over the trailing twelve months, while the specific employee count is not disclosed in public filings. These valuation and revenue metrics indicate that Synergy CHC Corp. functions as a micro-cap entity with a relatively small market presence compared to larger peers in the medical distribution landscape. The negative operating environment reflected in its financials suggests the company is currently navigating significant profitability challenges despite maintaining revenue streams through its international distribution network. The modest market cap combined with a revenue decline points to a firm that is likely in a restructuring phase or facing substantial headwinds that have compressed its valuation significantly below industry averages for established distributors.
वित्तीय स्वास्थ्य
Synergy CHC Corp. reported a total revenue of $30.38M for the trailing twelve months, yet this revenue generated a net income loss of $-12,341,208, revealing a severely distressed cost structure where expenses far exceed gross receipts. The company's EBITDA stands at $-8,325,415, which further underscores the depth of operational inefficiencies or one-time charges impacting the bottom line. Despite the net loss, the firm maintains positive free cash flow of $2.04M, indicating that it retains some financial flexibility to meet obligations without relying solely on external equity financing. The gross margin stands at 66.8%, suggesting that the core cost of goods sold is low relative to sales, yet this high margin is not sufficient to cover operating expenses. In contrast, the operating margin is a staggering -219.5%, and the profit margin is -40.6%, both figures indicating that operating costs and other expenses are consuming more than the gross profit generated by the business. The company holds $2.62M in cash against a debt obligation of $26.81M, creating a net debt position that significantly outweighs its liquid assets. While the debt-to-equity ratio is not available due to the company's negative equity position, the balance sheet is clearly leveraged given that debt exceeds cash reserves by a wide margin. The current ratio of 1.22 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, though the buffer is relatively thin. Return on Equity is not available due to the negative equity base, while Return on Assets stands at -39.9%, revealing that management is currently generating negative returns on the assets deployed in the business.
मूल्यांकन आकलन
The trailing P/E ratio is not available due to the company's net loss, whereas the forward P/E is calculated at 1.08, implying that the market is pricing in a rapid turnaround or significant future earnings recovery despite current losses. The price-to-book ratio is -0.87, which indicates that the market capitalizes the company at a value below its book value, a scenario common for distressed firms or those with substantial liabilities. The price-to-sales ratio is 0.24, suggesting that the stock trades at a fraction of its revenue, which is a typical valuation for small-cap healthcare firms facing profitability issues. Additionally, the EV/EBITDA multiple is -3.78, reflecting the negative earnings power and the difficulty in applying standard enterprise value metrics to a loss-making entity. The 52-week high is $4.08 and the 52-week low is $0.64, meaning the stock has experienced extreme volatility within a range of over 500% during the past year. The beta of 1.47 indicates that the stock's price volatility is significantly higher than the broader market, moving roughly 47% more aggressively than the S&P 500. These valuation metrics collectively suggest a high-risk profile where the market is pricing in potential distress rather than growth stability. The discrepancy between the forward P/E and the lack of a trailing P/E highlights the speculative nature of the current pricing.
Growth & Income
Synergy CHC Corp. experienced a revenue growth rate of -41.0% year-over-year, while earnings growth is not available due to the negative earnings base, indicating a sharp contraction in business scale. The absence of earnings growth data reinforces the severity of the financial decline, as the company is unable to grow profits while simultaneously shrinking its top line. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means it retains all earnings or losses rather than distributing cash to shareholders. This zero payout ratio is consistent with a non-dividend payer that must reinvest limited resources into survival and restructuring rather than shareholder returns. The overall growth and income profile is characterized by significant revenue contraction and a complete lack of dividend income, positioning the stock as a speculative play for investors seeking exposure to the healthcare sector without reliance on current profitability. The combination of negative revenue growth and a lack of cash distributions suggests the firm is in a defensive posture rather than an expansion phase. The financial data paints a picture of a company that has prioritized operational continuity over financial engineering or shareholder wealth creation in the current fiscal period.